TaiGen Biotechnology Co (太景生技) yesterday announced that it had signed an agreement with China-based Zhejiang Medicine Co (浙江醫藥) that gives the latter exclusive rights to manufacture and commercialize nemonoxacin in China, excluding Hong Kong and Macau.
Nemonoxacin is a novel broad-spectrum non-fluorinated quinolone antibiotic under development for respiratory infections.
Under the terms of the agreement, TaiGen will be responsible for completing the phase 3 clinical trial for community-acquired pneumonia (CAP) in China.
Zhejiang Medicine will be responsible for the manufacturing, sales and marketing of nemonoxacin in China through its wholly owned subsidiary, Xinchang Pharmaceuticals Co (新昌製藥). TaiGen will retain full development and commercialization rights outside the licensed territory including Taiwan, the US, the EU and Japan.
The Taiwanese biotechnology company will receive an upfront payment of US$8 million from Zhejiang Medicine and will receive additional milestones, as well as between 7 and 11 percent of royalties on product sales. The term of the agreement is 20 years.
“Nemonoxacin has demonstrated efficacy and safety in CAP and diabetic foot infection in clinical trials,” TaiGen chairwoman and chief executive officer Hsu Ming-chu (許明珠) told a press conference in Taipei.
“In particular, nemonoxacin has excellent efficacy against drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and quinolone-resistant MRSA. Nemonoxacin is taken once a day and available in both oral and intravenous formulations,” she said.
TaiGen is completing a phase 3 CAP trial with more than 500 patients from Taiwan and China, and the company expects to file new drug applications in Taiwan and China simultaneously early next year.
According to healthcare information, services and technology provider IMS Health Inc, the global sales of antibiotics amounted to approximately US$11 billion last year and account for almost 20 percent of total pharmaceuticals sales.
The rate of antibiotic-resistant infections in China is among the highest in the world.
According to IMS, global sales of nemonoxacin for CAP and diabetic foot infection could reach US$1.2 billion a year, Hsu said.
She added that TaiGen chose Zhejiang Medicine Co as a partner because it was a first-class pharmaceutical company in China, with a strong antibiotics-marketing team.
“China is the world’s fastest-growing pharmaceutical market. It is poised to overtake Japan as the second-largest pharmaceutical market,” Hsu said. “This partnership will not only set a new record for pharmaceutical licensing involving a Taiwanese and a Chinese company, but hopefully will also become a model for future collaborations.”
“With the conclusion of the partnership in China, we will actively pursue nemonoxacin licensing discussions in other territories, such as the European Union,” Hsu said.
TaiGen currently has Burixafor for stem cell mobilization and TG-2349, a HCV NS3-4A Protease Inhibitor, under phase 2 and phase 1 clinical trials respectively, which will be the company’s focus after nemonoxacin, Hsu added.
Meanwhile, Academia Sinica President Wong Chi-huey (翁啟惠) said yesterday that Taiwan should step up its efforts to expand cooperation with China in clinical research, after the two sides concluded a medical cooperation agreement in December 2010.
Citing Taiwan’s strength in research on diseases that affect only ethnic Chinese, Wong said that clinical trial programs carried out in conjunction with Chinese researchers would further benefit medical research in the field. He made the remark on the second day of a four-day forum to review Taiwan’s policies on the biotech industry.
Additional reporting by CNA
MULTIFACETED: A task force has analyzed possible scenarios and created responses to assist domestic industries in dealing with US tariffs, the economics minister said The Executive Yuan is tomorrow to announce countermeasures to US President Donald Trump’s planned reciprocal tariffs, although the details of the plan would not be made public until Monday next week, Minister of Economic Affairs J.W. Kuo (郭智輝) said yesterday. The Cabinet established an economic and trade task force in November last year to deal with US trade and tariff related issues, Kuo told reporters outside the legislature in Taipei. The task force has been analyzing and evaluating all kinds of scenarios to identify suitable responses and determine how best to assist domestic industries in managing the effects of Trump’s tariffs, he
TIGHT-LIPPED: UMC said it had no merger plans at the moment, after Nikkei Asia reported that the firm and GlobalFoundries were considering restarting merger talks United Microelectronics Corp (UMC, 聯電), the world’s No. 4 contract chipmaker, yesterday launched a new US$5 billion 12-inch chip factory in Singapore as part of its latest effort to diversify its manufacturing footprint amid growing geopolitical risks. The new factory, adjacent to UMC’s existing Singapore fab in the Pasir Res Wafer Fab Park, is scheduled to enter volume production next year, utilizing mature 22-nanometer and 28-nanometer process technologies, UMC said in a statement. The company plans to invest US$5 billion during the first phase of the new fab, which would have an installed capacity of 30,000 12-inch wafers per month, it said. The
Taiwan’s official purchasing managers’ index (PMI) last month rose 0.2 percentage points to 54.2, in a second consecutive month of expansion, thanks to front-loading demand intended to avoid potential US tariff hikes, the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. While short-term demand appeared robust, uncertainties rose due to US President Donald Trump’s unpredictable trade policy, CIER president Lien Hsien-ming (連賢明) told a news conference in Taipei. Taiwan’s economy this year would be characterized by high-level fluctuations and the volatility would be wilder than most expect, Lien said Demand for electronics, particularly semiconductors, continues to benefit from US technology giants’ effort
‘SWASTICAR’: Tesla CEO Elon Musk’s close association with Donald Trump has prompted opponents to brand him a ‘Nazi’ and resulted in a dramatic drop in sales Demonstrators descended on Tesla Inc dealerships across the US, and in Europe and Canada on Saturday to protest company chief Elon Musk, who has amassed extraordinary power as a top adviser to US President Donald Trump. Waving signs with messages such as “Musk is stealing our money” and “Reclaim our country,” the protests largely took place peacefully following fiery episodes of vandalism on Tesla vehicles, dealerships and other facilities in recent weeks that US officials have denounced as terrorism. Hundreds rallied on Saturday outside the Tesla dealership in Manhattan. Some blasted Musk, the world’s richest man, while others demanded the shuttering of his